2215 Yukon Street
Vancouver, BC V5Y 0A1
Full-time employees: 525
|Dr. Carl L.G. Hansen Ph.D.||CEO, Pres & Chairperson||711.47k||1.85M||1975|
|Mr. Andrew Booth M.B.A.||Chief Financial Officer||642.42k||510.82k||1974|
|Dr. Veronique Lecault Ph.D.||COO & Director||645.07k||N/A||1985|
|Mr. Tryn T. Stimart Esq., J.D.||Chief Legal Officer, Chief Compliance Officer & Corp. Sec.||644.4k||N/A||1970|
|Mr. Neil Aubuchon M.B.A.||Chief Commercial Officer||684.81k||N/A||1970|
|Dr. Ester Falconer Ph.D.||Chief Technology Officer||N/A||N/A||1975|
|Mr. Bo Barnhart Ph.D.||Scientific Director||N/A||N/A||N/A|
|Ms. Tiffany Chiu B.Sc., Ph.D.||VP of Communications||N/A||N/A||N/A|
|Alexandra Weirich M.Sc.||Mang. of Marketing & Communications||N/A||N/A||N/A|
|Graham Craig M.Sc.||Director of Corp. Devel.||N/A||N/A||N/A|
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc.’s ISS governance QualityScore as of 1 June 2023 is 8. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 4; Compensation: 9.